Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride is an alpha‑1 adrenergic agonist. It binds to alpha‑1 receptors on the radial iris dilator muscle, causing the muscle to contract. This contraction pulls the iris outward, widening the pupil and contributing to the overall mydriatic effect when combined with tropicamide.

The specific dosage and administration schedule for Mydriasert are determined by the prescribing eye care professional based on the patient’s condition, age, and the intended procedure. Clinicians select the appropriate number of drops and timing to achieve the desired level of pupil dilation.

Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the individual situation and discuss possible alternatives when necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mydriasert. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mydriasert combines phenylephrine, an alpha‑1 agonist, with tropicamide, a muscarinic antagonist, offering rapid and sustained dilation. Compared with single‑agent preparations, this combination often achieves a broader pupil size more quickly, reducing the need for multiple drops and improving procedural efficiency.

Mydriasert should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture to maintain stability. Do not freeze the product, and keep the container tightly closed when not in use.

Mydriasert is applied topically to the eye as a drop. The prescribing clinician determines the number of drops and timing, typically instilling the solution into the conjunctival sac of the target eye(s) a few minutes before the examination or procedure.

Serious risks include acute angle‑closure glaucoma, significant systemic hypertension, and rare cardiac arrhythmias. Patients with narrow‑angle glaucoma or uncontrolled cardiovascular disease should be evaluated carefully before use, and any signs of severe adverse reactions require immediate medical attention.

Mydriasert should be avoided in individuals with known hypersensitivity to phenylephrine, tropicamide, or any excipients in the formulation. It is also contraindicated in patients with narrow‑angle or acute angle‑closure glaucoma, and caution is advised for those with severe cardiovascular disorders.